Swiss biotech partnership brings Mitopure® to skincare, clinically proven to energize cellular mitochondria.
Biotech powers Lancôme innovation
Lancôme centers skin longevity science in its strategy. In addition, partners with Swiss biotech Timeline®, pioneer of Mitopure®, activating skin cell mitophagy.
Backed by $50M+ R&D, Mitopure® is pure Urolithin A. Thus, it restores mitochondrial energy, targeting visible biological skin aging.
Proactive skincare era dawns
L’Oréal Group led beauty into longevity investing in Timeline® 2024. Now Lancôme launches Mitopure®-infused line with proprietary actives, industry benchmark.
“Longevity is radical progress, beyond looks. We redefine aging with cutting-edge science,” states Vania Lacascade, Lancôme Global President. Meanwhile, biotech democratizes cellular benefits.
Longevity ecosystem expands
Integrates Absolue Longevity The Soft Cream with Absolue PDRN™ and Cell BioPrint™ via NanoEnTek proteomics. In turn, shifts reactive correction to data-driven prediction.
Mitopure® line debuts at AAD convention, March 2026. Thus, holistic science preserves skin “healthspan” comprehensively.
About Timeline® and Lancôme
Timeline® advances cellular health with 15 years research, 50 patents. Nestlé Health Science and L’Oréal backed, extends Mitopure® to global skincare.
Founded 1935, Lancôme blends science, emotion empowering women. In Brazil, premium portfolio emphasizes sustainable innovation, vitality.
